IMPORTANCE Unencapsulated Haemophilus influenzae frequently causes noninvasive upper respiratory tract infections in children but can also cause invasive disease, especially in older adults. A number of studies have reported an increased incidence in neonates and suggested that pregnant women may have an increased susceptibility to invasive unencapsulated H influenzae disease. OBJECTIVE To describe the epidemiology, clinical characteristics, and outcomes of invasive H influenzae disease in women of reproductive age during a 4-year period. DESIGN, SETTING, AND PARTICIPANTS Public Health England conducts enhanced national surveillance of invasive H influenzae disease in England and Wales. Clinical questionnaires were sent prospectively to general practitioners caring for all women aged 15 to 44 years with laboratory-confirmed invasive H influenzae disease during 2009-2012, encompassing 45 215 800 woman-years of follow-up. The final outcome was assessed in June 2013. EXPOSURES Invasive H influenzae disease confirmed by positive culture from a normally sterile site.
H aemophilus influenzae is a gram-negative coccobacillus that can cause severe invasive disease in humans. Haemophilus influenzae can be distinguished into 6 distinct serotypes (a-f) according to its polysaccharide capsule or it can be unencapsulated. Haemophilus influenzae serotype b is the most virulent and, prior to routine vaccination in 1992, was responsible for more than 80% of all invasive H influenzae disease and a major cause of bacterial meningitis in young children. 1, 2 Routine vaccination against H influenzae serotype b has resulted in rapid and sustained declines in incidence across all age groups through direct and indirect (herd) protection. In England and Wales, invasive H influenzae serotype b disease incidence among children younger than 5 years decreased from 22.9/100 000 in 1991 to 0.06/100 000 (equivalent to 2 cases) in 2012. 3 Consequently, invasive infections caused by unencapsulated H influenzae have become comparatively more common. 2, 4 Unencapsulated H influenzae is a common colonizer of the human respiratory tract and frequently causes noninvasive upper respiratory tract infections. 5 Occasionally, unencapsulated H influenzae may cause invasive disease, including pneumonia, septicemia, and meningitis. 2, 4 A previous European study 2 noted that neonates had a greater than 10-fold increased risk of invasive unencapsulated H influenzae disease compared with H influenzae serotype b, mainly during the first week of life, suggesting perinatal infection, which was consistent with a number of previous reports. 6, 7 It was also noted that, although invasive unencapsulated H influenzae disease was more common in males than in females overall, the opposite was true for those aged 18 to 44 years. 2 Other population-based surveillance studies have suggested an increased risk of invasive H influenzae disease during pregnancy, although the analyses were based on only 5 pregnant cases, 7 7 cases, 8 9 cases, 9 and 11 cases. 10 Several case reports and small case series have suggested that H influenzae (mainly unencapsulated H influenzae but also encapsulated H influenzae) can cause serious illness in pregnant women, often resulting in fetal death or premature birth with serious illness in the infant. [11] [12] [13] [14] [15] To better understand the association between invasive H influenzae disease and pregnancy, Public Health England initiated enhanced national surveillance of all laboratoryconfirmed invasive H influenzae cases in women of childbearing age during 2009-2012. The objective of this study was to describe the epidemiology, clinical characteristics, and outcomes of invasive H influenzae disease in pregnant and nonpregnant women in England and Wales.
Methods
Public Health England undertakes enhanced national surveillance for invasive H influenzae disease through a combination of isolate submission, routine laboratory reporting, and clinical reporting schemes as previously described. 3, 16 Briefly, the Haemophilus Reference Unit of Public Health England conducts species confirmation and serotyping of all invasive clinical H influenzae isolates for all National Health Service (NHS) hospital laboratories in England and Wales as part of an enhanced national surveillance effort. Public Health England also receives electronic reports of clinically significant infections from NHS hospitals and routinely requests submission of clinical isolates to the Haemophilus Reference Unit if this has not already been done. All reports are reconciled into a single database. During 2009-2012, clinicians caring for 15-to 44-yearold women with laboratory-confirmed invasive H influenzae disease were asked to complete a standardized questionnaire 17 approximately 3 months after infection.
Nonresponders and those with incomplete or inconsistent surveillance forms were followed up by letter, telephone, or both. For fatal cases, the cause of death was ascertained from postmortem reports (if performed) or death registration data provided by the Office for National Statistics to Public Health England for surveillance purposes, or both.
Invasive H influenzae disease was defined as the isolation of H influenzae from a normally sterile site. Localized H influenzae infections such as epiglottitis or pneumonia were included if accompanied by a sterile site isolate. Isolates were confirmed as H influenzae by their growth requirement for X and V factors and ompP2-specific polymerase chain reaction positivity. 3, 16 Haemophilus influenzae capsulation status was determined by polymerase chain reaction using bexAspecific primers. Capsular type was confirmed as types a through f by using capsule-specific primers and slide agglutination.
Ethical Approval
Public Health England has approval under the Patient Information Advisor Group §60 of the Health and Social Care Act of 2001 (now subsumed into the Heath Research Authority with §60 now being §251 of the National Health Service Act of 2006) to process confidential patient information for public health purposes. The enhanced surveillance did not require additional ethical approval.
Statistical Analysis
Data were analyzed using Stata version 11.0 (StataCorp). The α level was set at .05 for all statistical tests. Data that did not follow a normal distribution were described as medians with interquartile ranges; differences were compared using the Kruskal-Wallis or Wilcoxon rank sum test. Categorical variables were expressed as proportions with binomial 95% confidence intervals and compared using 2-sided χ 2 or Fisher exact tests. Bivariable logistic regression was used to investigate the relationships between variables using the largest group as the baseline and where appropriate, age in years was included as a continuous variable in the model. Models were assessed for goodness of fit using the Hosmer-Lemeshow goodness-of-fit test. Data from the Office for National Statistics on population 18 and maternity [19] [20] [21] [22] (including live births, miscarriages, stillbirths, and terminations) were used to ascertain denominator populations. Incidence rates with Poisson 95% confidence intervals for pregnant and nonpregnant women along with incidence rate ratios for pregnant vs nonpregnant women were calculated. Associations between pregnancy outcome, H influenzae strain, and maternal
Results
During 2009-2012 (encompassing 45 215 800 woman-years), 2568 cases of invasive of H influenzae were identified, including 1906 isolates (74.2%; 95% CI, 72.5%-75.9%) that were serotyped. Women of reproductive age accounted for 8.7% (95% CI, 7.7%-9.9%; n = 224) of all cases and 9.0% (95% CI, 7.7%-10.3%; n = 171) of cases with serotyped isolates. Clinical questionnaires were completed for all 171 cases with serotyped isolates. There were 144 cases (84.2%; 95% CI, 77.9%-89.3%) with unencapsulated H influenzae, 11 cases (6.4%; 95% CI, 3.3%-11.2%) with H influenzae serotype b, and 16 cases (9.4%; 95% CI, 5.4%-14.7%) with other encapsulated serotypes, including 14 cases (8.2%; 95% CI, 4.5%-13.4%) with H influenzae serotype f and 2 cases (1.2%; 95% CI, 0.1%-4.2%) with H influenzae serotype e ( Table 1 ). The median age of women at diagnosis was 32.3 years (interquartile range, 24.7-38.7 years), which was not significantly different across the H influenzae groups (Kruskal-Wallis χ 2 = 2.88, P = .24) ( Table 1) .
Overall, 65 of 171 women (38.4%; 95% CI, 30.7%-45.7%) had at least 1 concurrent condition reported (Table 1) , which was not associated with age at infection or serotype. The most prevalent concurrent condition was chronic respiratory disease followed by malignancy or immunosuppression. Bacteremia was the most common presentation (53.8%), followed by pneumonia (29.2%) ( Table 1) . Few women presented with meningitis (n = 7) and only 1 was due to encapsulated H influenzae (serotype f). Nine women (all with unencapsulated H influenzae) presented with pelvic inflammatory disease.
By June 2013, 12 women had died but only 4 deaths were associated with H influenzae. In 8 cases, the cause of death was attributed to an underlying medical condition and occurred more than 30 days after infection. The case-fatality rate associated with H influenzae was 2.3% (95% CI, 0.6%-5.9%; 4/171) and the responsible strains were unencapsulated H influenzae (n = 2), H influenzae serotype b (n = 1), and H influenzae serotype f (n = 1). Three deaths were due to pneumonia; 1 woman had recently undergone chemotherapy for breast cancer, 1 had chronic liver and neurological disease, and 1 was previously healthy but died from myocarditis as a complication of pneu- (Table 2) . Of the 3 pregnant women with encapsulated H influenzae, 2 were serotype f and 1 was serotype b. None of the women had concurrent conditions at the time of infection (χ 2 = 0.60, P = .44). Two of these women presented with bacteremia (1 with H influenzae serotype b and 1 with H influenzae serotype f). One woman presented with pneumonia. After adjusting for the presence of concurrent conditions, pregnant women were 8.5 (95% CI, 2.3-30.9; P < .001) times more likely to develop invasive unencapsulated than encapsulated H influenzae.
Three additional invasive H influenzae cases (2 unencapsulated and 1 serotype f) were diagnosed a few days after the 
Pregnancy Outcome
The eventual outcome for all 75 pregnancies (77 fetuses) was recorded, including 72 cases (74 fetuses) with unencapsulated H influenzae. Among the unencapsulated H influenzae pregnancies, 43 of 74 fetuses (58.1%; 95% CI, 46.1%-69.5%) were miscarried, 2 were stillborn (2.7%; 95% CI, 0.3%-9.4%), and 29 were live born (39.2%; 95% CI, 36.3%-51.6%), including 11 (37.9%; 95% CI, 20.7%-57.7%; n=29) who were born prematurely (<37 weeks' gestation) (Figure) . For the remaining 3 pregnancies that did not have unencapsulated H influenzae, 1 was miscarried, 1 was stillborn, and 1 was live born (Figure) . Forty-four of the 47 cases (93.6%; 95% CI, 82.5%-98.7%) with unencapsulated H influenzae infections during the first 24 weeks of pregnancy ended in miscarriage and 3 of 47 (6.4%; 95% CI, 1.3%-17.5%) resulted in extremely premature birth. Two women, who both developed unencapsulated H influenzae at week 12, recovered from their infection and went on to give birth to live-born infants at weeks 25 and 28. A third woman developed unencapsulated H influenzae at 23 weeks' gestation and went into premature labor; the neonate survived the birth but died within 3 months due to complications of extreme prematurity. Two multiple pregnancy cases were recorded, one at 22 weeks' gestation that ended in miscarriage and the second at 28 weeks' gestation in which one infant survived and the other was stillborn.
Two of 28 ( The incidence of pregnancy loss was 61.0 (95% CI, 49.2-72.0) per 100 pregnancies among women with invasive H influenzae disease and 60.8 (95% CI, 44.4-81.0) per 100 pregnancies for unencapsulated H influenzae. Assuming an estimated incidence of 21 per 100 pregnancies lost in the population, 22 the crude incidence rate ratio for pregnancy loss was 2.91 (95% CI, 2.13-3.88) for all serotypes of H influenzae and 2.90 (95% CI, 2.11-3.89) for unencapsulated H influenzae.
Discussion
The incidence of laboratory-confirmed invasive H influenzae disease was low at 0.50 per 100 000 women of reproductive age in England and Wales. Pregnant women were at significantly higher risk of infection mainly due to unencapsulated H influenzae disease and were usually younger and healthier than nonpregnant women. Moreover, although none of the pregnant women died, 73 of the 75 pregnancies were associated with miscarriage or labor at the time of infection. In particular, all but 3 infections occurring during the first 24 weeks of pregnancy ended in miscarriage, whereas the remaining 3 resulted in extremely premature births. Given that around 20% of known pregnancies are lost prior to 25 weeks' gestation (the point at which the UK records the loss as a Copyright 2014 American Medical Association. All rights reserved. stillbirth), 22 pregnancy loss following invasive H influenzae disease was 2.91-fold higher than the UK national average. After 24 weeks' gestation, invasive unencapsulated H influenzae disease was also associated with birth of the infant at the time of infection, stillbirth in 3 cases, and premature birth in one-third of cases. In addition to the serious infection, these infants were also at risk for the long-term complications of prematurity. The finding that 3 women were diagnosed with invasive H influenzae disease shortly after giving birth emphasizes the importance of monitoring mothers as well as newborns postnatally for sepsis.
The association between H influenzae and pregnancy has been difficult to assess because the infection is relatively uncommon. Four published studies were identified that described the epidemiology of invasive H influenzae disease in pregnant women, totaling 32 pregnancies. 7,1 0 A US population-based study estimated that pregnancy was associated with a 6-fold increased risk of invasive H influenzae disease, 10 whereas in Iceland, the risk was estimated to be 25-fold higher. 9 Both estimates had wide confidence intervals due to the small number of cases (11 and 9 cases, respectively), with limited clinical data for the mother or infant. The association between unencapsulated H influenzae and pregnancy is consistent with recent studies reporting significantly higher morbidity associated with other respiratory pathogens such as Streptococcus pneumoniae and group A streptococci in pregnant women compared with nonpregnant women. 23 The incidence of invasive unencapsulated H influenzae disease during pregnancy in the current study (3/100 000) was similar to a recent US study for S pneumoniae (4/100 000), group A streptococci (2/100 000), and group B streptococci (4/100 000). 23 The increased incidence of invasive H influenzae disease among pregnant women was reminiscent of Listeria monocytogenes infections but with a much higher rate of fetal loss. In a recent US study, 16.9% of Listeria cases were associated with pregnancy, 20.3% of which resulted in fetal loss, and 80% of which occurred during the first 24 weeks of pregnancy, 24 whereas a Danish study reported 33.3% fetal loss among pregnant women with L monocytogenes infections. 25 Although unencapsulated H influenzae commonly colonizes the human upper respiratory tract, it can also colonize the female reproductive tract and can cause pelvic inflammatory disease. 14 Case reports have suggested an association between unencapsulated H influenzae colonization of the reproductive tract and premature rupture of membranes during pregnancy, leading to miscarriage, septic abortion, stillbirth, and premature birth. 12, 13 Carriage studies, however, found that only 1.8/1000 pregnant women carry unencapsulated H influenzae in their genital tract, 26 although prevalence was higher (8/110; 7.3%) in women with preterm rupture of membranes, 27 suggesting a high case to carrier ratio. A high case to carrier ratio has also been reported for S pneumoniae, which rarely (<1%) colonizes the female genital tract but can cause serious invasive disease in newborns. 28 This is in contrast to group B streptococci, which commonly colonize the reproductive tract during pregnancy but only occasionally cause invasive disease in newborns. 29 There is speculation that the genital tract unencapsulated H influenzae strains are different from those colonizing the nasopharynx, 30 which is worthy of further research.
During the surveillance period, although nearly all surviving neonates were admitted to the neonatal intensive care unit with suspected sepsis, only 1 had a positive H influenzae isolate from a sterile site. Cultures from the neonates were likely negative because their mothers would have received intrapartum antibiotics. This finding suggests that the burden of neonatal unencapsulated H influenzae disease may be significantly underestimated because maternal peripartum infections are usually not considered when reporting neonatal sepsis. Moreover, miscarriages and stillbirths do not routinely undergo postmortem examination to identify an infectious etiology. 31 The finding that all but 1 live-born infant survived irrespective of gestational age at birth was reassuring, but there is increasing evidence for both acute complications and longterm adverse neurodevelopmental outcomes among survivors of neonatal sepsis, particularly those born prematurely. 32 
Limitations
As with all national surveillance programs, it is possible that not all cases of invasive H influenzae are reported to Public Health England. However, automated electronic reporting of clinically significant infections by NHS hospital laboratories not only allows high case ascertainment, but also avoids bias in case reporting by age, sex, clinical characteristics, or outcome. Ascertainment was further supported by regular reminders to microbiologists to submit invasive isolates to Public Health England for serotyping, along with actively seeking isolate submission for cases reported electronically. Isolate submission rates remain consistently high because NHS laboratories no longer perform serotyping locally; reports without serotype data are nearly always because the isolate became unviable during transit or was not able to be recultured at Public Health England. Haemophilus influenzae serotyping remains a key surveillance priority, not only for monitoring the serotype b immunization program, but also to identify serotype b vaccine failure cases to ensure that close contacts of serotype b cases are protected through chemoprophylaxis and vaccination, and to identify and control H influenzae serotype b outbreaks. 33 Local health protection teams, therefore, play a key role in facilitating case reporting and isolate submission to Public Health England. 33 Support for the program, for example, was shown by complete clinical follow-up of all cases in this study. By routinely following up all H influenzae cases across all age groups, the enhanced surveillance achieves unbiased and near-complete case ascertainment, 31, 34 with stable trends over time, and the ability to rapidly detect small changes in serotype-specific disease rates within specific age groups. 3, 16, 35 Although it is possible that the higher unencapsulated H influenzae rates in pregnant women might have resulted from clinicians having a lower threshold for investigating and treating pregnant women compared with nonpregnant women, the finding that almost all infections were associated with miscarriage, stillbirth, or premature birth provides evidence of the severity of infection in pregnant women. Invasive H influen-
